Is INOVIO PHARMACEUTICALS, INC. (INO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 9.9% / 30% | 78.7% / 30% | 1.0% / 30% | 2189.14% / 5% | ✗ NOT HALAL |
| DJIM | 9.9% / 33% | 78.7% / 33% | 1.0% / 33% | 2189.14% / 5% | ✗ NOT HALAL |
| MSCI | 10.5% / 33% | 83.1% / 33% | 1.1% / 33% | 2189.14% / 5% | ✗ NOT HALAL |
| S&P | 9.9% / 33% | 78.7% / 33% | 1.0% / 33% | 2189.14% / 5% | ✗ NOT HALAL |
| FTSE | 10.5% / 33% | 83.1% / 33% | 1.1% / 50% | 2189.14% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -132871.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -183.5% | |
| Return on Assets (ROA) | -57.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$89M |
| Free Cash Flow | -$89M |
| Total Debt | $9M |
| Debt-to-Equity | 38.9 |
| Current Ratio | 1.4 |
| Total Assets | $74M |
Price & Trading
| Last Close | $1.55 |
| 50-Day MA | $1.65 |
| 200-Day MA | $1.94 |
| Avg Volume | 1.2M |
| Beta | 1.8 |
|
52-Week Range
$1.30
| |
About INOVIO PHARMACEUTICALS, INC. (INO)
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is INOVIO PHARMACEUTICALS, INC. (INO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), INOVIO PHARMACEUTICALS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is INOVIO PHARMACEUTICALS, INC.'s debt ratio?
INOVIO PHARMACEUTICALS, INC.'s debt ratio is 9.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.5%.
What are INOVIO PHARMACEUTICALS, INC.'s key financial metrics?
INOVIO PHARMACEUTICALS, INC. has a market capitalization of $111M, and revenue of $65,343. Return on equity stands at -183.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.